IGF2BP3 and lung adenocarcinoma: IGF2BP3, which is highly expressed in lung adenocarcinoma (LUAD), inhibits ferroptosis by binding to key ferroptosis-related proteins such as GPX4, SLC3A2, ACSL3, and FTH1, making it a promising target for anticancer therapies (Xu X. et al., 2022).